Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Almirall

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Almirall's 2013 sales performance.

AstraZeneca scores in final lung disease drug trials

AstraZeneca scores in final lung disease drug trials from big players such as Boehringer, GlaxoSmithKline, Novartis and Forest/Almirall.

Transforming times at AstraZeneca

Transforming times at AstraZeneca In 2014 alone the company completed the acquisition of all diabetes assets from its deal with Bristol-Myers Squibb; boosted its respiratory business with the acquisition of Almirall's respiratory franchise;

AZ adds to respiratory portfolio with Actavis drugs

AZ adds to respiratory portfolio with Actavis drugs Follows deal to acquire Almirall’s franchise in asthma and COPD. AstraZeneca has expanded its presence in respiratory disease with the $700m acquisition of Actavis' portfolio in the US and Canada. ... It follows a similar deal agreed in July last year

Deal Watch table for November 2014

Deal Watch table for November 2014 Pharma business unit. Business unit divestment. 3, 200. Almirall / AstraZeneca.

AZ's new COPD therapy gets green light in Europe

AZ's new COPD therapy gets green light in Europe AZ owns the rights to develop and commercialise Duaklir in the EU after taking ownership of former partner Almirall's respiratory portfolio in a $1.2bn deal that was completed last

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Thrive Agency

We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...

Latest intelligence

Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...
Is communication failing us?
Compelling people to care in a world oversaturated with news and information...